Story

UBS Warns of 'Negative Catalyst' for Nike, Cuts Price Target on Weakening Demand

ENTHMSVIIDZHZH-TWJAKOHI
Sep 20, 20262 min read
UBS Warns of 'Negative Catalyst' for Nike, Cuts Price Target on Weakening Demand

Summary

Analysts at UBS have lowered their price target on Nike, citing a high risk of a significant earnings miss and downward guidance revision in the company's upcoming quarterly report.

Text size
Background

Nike (NKE) faces a high risk of a significant earnings miss and further stock price declines when it reports its fiscal 2027 first-quarter results, according to a new research note from UBS. The bank's analysts warned of a "negative catalyst" for the sportswear giant, advising investors to remain on the sidelines despite the stock's recent pullback.

Analyst Warning

UBS analyst Jay Sole maintained a "Neutral" rating on Nike shares but cut the 12-month price target by 13% to $42 from a previous $48. The bank's forecast for Nike's Q1 earnings per share (EPS) is $0.39, which is $0.05 below the Wall Street consensus of $0.44.

More significantly, UBS anticipates that Nike's management will issue weak guidance for the second quarter and lower its full-year forecast for fiscal 2027. The note projects Q2 EPS guidance in a range of $0.31 to $0.43, well below the market's expectation of $0.53. "Sentiment is bearish, but our conversations with investors suggest the market underestimates how much EPS could fall on this print," Sole wrote.

Global Channels Under Pressure

UBS's channel checks and data analysis point to deteriorating demand trends across Nike's key product categories and geographic markets. The report highlighted several areas of concern:

Sample IUX Markets – In-articleAd
  • North America: Direct-to-consumer (DTC) sales are projected to fall by a mid-single-digit percentage in Q1, a steeper decline than the -0.4% consensus forecast. This is attributed to weakening demand for core lifestyle products like the Dunk sneaker line.
  • Greater China: Sales in the region are expected to decline by 14.0% year-over-year. The drop is reportedly driven by high inventory levels, reduced participation from distributors in e-commerce, and Nike's plan to cut over 1,000 third-party digital partners.
  • Europe: Transaction data suggests a 22.1% year-over-year decline in European DTC sales for the first quarter. UBS also noted that Nike is losing market share in the lifestyle category to competitors such as On, Hoka, and Adidas.
  • Converse: The brand is expected to see a dramatic 30% year-over-year drop in sales.

Market Positioning and Outlook

The analyst warning comes as bearish sentiment toward Nike appears to be growing. Short interest in the stock has climbed to a five-year high, reaching 6.4% of the free float. UBS's quantitative data shows that short positions in Nike are crowded relative to both its peers and its own historical levels.

Reflecting these challenges, UBS has lowered its full-year fiscal 2027 EPS forecast for Nike by 16% to $1.30, compared to a buy-side consensus of $1.55. Despite the stock's valuation contracting to a forward price-to-earnings ratio of 21x from its five-year average of 34x, the bank believes the risk of downward earnings revisions remains high. The options market is currently pricing in a potential stock price move of approximately 8.0% around the upcoming earnings release.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST